University of Minnesota. Driven to Discover.
Admission to an Ebola treatment unit was tied to a 38% drop in secondary cases.
"I would view the results . . . in an optimistic light," said lead author Richard Davey after the drug showed more than 90% efficacy.
The child's case is the 4th—including a death—from the same family in Forecariah district.
Also, phase 2 trials just launched for two prime-boost Ebola vaccine regimens.
Funding will be used to continue trials of BCX4430 and prepare for its large-scale manufacture.
The findings clear the way for the next step, which may require a change in venue.
The virus may be more stable than a study in August found.
Other Ebola developments include the departure of Cuba's team from Liberia, new information on evacuee contact monitoring, and outbreak case totals.
Steeply dropping cases, though, may cause the NIAID to vary from the original trial design.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.